TCI Wealth Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$100K Hold
11,000
– – ﹤0.01% 282
2026
Q2
$72.7K Hold
11,000
– – ﹤0.01% 262
2026
Q1
$79.6K Hold
11,000
– – ﹤0.01% 247
2025
Q4
$83K Hold
11,000
– – ﹤0.01% 250
2025
Q3
$64.9K Buy
+11,000
New +$59.9K ﹤0.01% 261

Other funds holding EPRX

TCI Wealth Advisors's EPRX Position: Q3 2026 in Review

TCI Wealth Advisors held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 11,000 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #282.

TCI Wealth Advisors first reported a position in EPRX in Q3 2025 and has held it in 5 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • TCI Wealth Advisors held 11,000 shares of Eupraxia Pharmaceuticals worth $100K as of Q3 2026.
  • TCI Wealth Advisors left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of TCI Wealth Advisors's portfolio in Q3 2026, its #282 holding.
  • TCI Wealth Advisors first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on TCI Wealth Advisors's 13F filing for Q3 2026, filed 30 Oct 2026.